Inactive Instrument

Press Releases Beigene Ltd Hong Kong S.E.

Equities

End-of-day quote Hong Kong S.E. Other stock markets
- ^HKD	-

07-16	Nomura Adjusts BeiGene Price Target to $266 From $248.41, Maintains Buy Rating	MT
07-16	Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Zymeworks to Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024	07-12	AQ
Neuroendocrine Tumors Pipeline 2024 \| Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene	07-12	AQ
Advanced Hepatocellular Carcinoma Pipeline 2024 \| CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene	07-05	AQ
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	06-17	AQ
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	06-14	BU
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region	06-13	BU
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	06-04	BU
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	05-28	AQ
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	05-24	BU
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	05-14	BU
BeiGene Reports First Quarter 2024 Financial Results and Business Updates	05-08	BU
BeiGene : Financial Information - Form 8-K	04-26	PU
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report	04-26	BU
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting	04-24	BU
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	04-23	BU
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy	03-15	AQ
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	03-14	BU
First Doses of BRUKINSA provided to Patients with Chronic Lymphocytic Leukemia in Low and Middle-Income Countries under Collaboration of the Max Foundation, BeiGene, and the BeiGene Foundation	03-14	AQ
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation	03-13	BU
BRINGING LIGHT TO THE DARKNESS OF CANCER, BEIGENE NAMED NATIONAL PARTNER OF SURVIVORSHIP AND HOPE FOR THE LEUKEMIA & LYMPHOMA SOCIETY'S LIGHT THE NIGHT	03-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Beigene Ltd Hong Kong S.E.

Equities

Press Releases

Filters